Container with multi-phase composition for use in diagnostic and therapeutic applications
AssigneeBristol-Myers Squibb Medical Imaging, Inc.
InventorsEvan C. Unger, Terry Matsunaga, David Yellowhair
Life of this patent
Estimating the term…
Abstract
A container comprising an aqueous lipid suspension and a gaseous phase substantially separate from the aqueous stabilizing phase, useful in diagnostic imaging such as ultrasound and magnetic resonance imaging and in therapeutic applications, is disclosed.
Claims155
A container comprising an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase is substantially separate from said aqueous lipid suspension phase and consists essentially of a single perfluorocarbon gas, and said aqueous lipid suspension phase comprises at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
A container which contains a composition for use in diagnostic imaging, wherein the composition comprises an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase is substantially separate from said aqueous lipid suspension phase and consists essentially of a single perfluorocarbon gas, and said aqueous lipid suspension phase comprises at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
A container comprising an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase comprises a fluorinated gas and is substantially separate from said aqueous lipid suspension phase, and said aqueous lipid suspension phase comprises at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
A container which contains a composition for use in diagnostic imaging, wherein the composition comprises an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase comprises a fluorinated gas and is substantially separate from said aqueous lipid suspension phase, and said aqueous lipid suspension phase comprises at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
A container comprising an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase is substantially separate from said aqueous lipid suspension phase and comprises a substantially insoluble gas in combination with a soluble gas, and said aqueous lipid suspension phase comprises lipids, wherein said lipids comprise at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
A container which contains a composition for use in diagnostic imaging, wherein the composition comprises an aqueous lipid suspension phase and a gaseous phase, wherein said gaseous phase is substantially separate from said aqueous lipid suspension phase and comprises a substantially insoluble gas in combination with a soluble gas, and said aqueous lipid suspension phase comprises at least one phosphatidylcholine, at least one phosphatidylethanolamine, and at least one phosphatidic acid, wherein said phosphatidylcholine is selected from the group consisting of dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylcholine, and distearoyl-phosphatidylcholine;
- said phosphatidylethanolamine is selected from the group consisting of dipalmitoylphosphatidylethanolamine, dioleoyl-phosphatidylethanolamine, and N-succinyl-dioleoyl-phosphatidylethanolamine;
- and said phosphatidic acid is dipalmatoylphosphatidic acid.
Dependencies are inferred from the claim text.